Eli Lilly and Amplitude form RNA vaccine partnership

Health sector partnership with potential to reduce costs and accelerate infectious disease vaccine development globally

Eli Lilly has entered a partnership with Amplitude, a company founded by former Gateway Labs alumni, to develop an RNA vaccine platform for infectious diseases. This collaboration targets faster, cheaper vaccine production at scale. If the platform succeeds, it could lower barriers to global access for infectious disease vaccines by reducing development timelines and manufacturing costs. The outcome hinges entirely on the platform’s real-world performance—current progress remains in early stages. This partnership advances both health security and the availability of critical medical goods. The source material provides no additional detail beyond this partnership announcement, so the full implications remain with the original reporting team.

Source: Fierce Biotech